| Symbol | AQSZF |
|---|---|
| Name | AEQUUS PHARMACEUTICALS INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | V6C 1S4 Canada BC Suite 2820 200 Granville Street |
| Telephone | 604-336-7906 |
| Fax | — |
| — | |
| Website | http://www.aequuspharma.ca |
| Incorporation | CA |
| Incorporated On | 2013 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Smythe LLP.; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: TSX Venture Exchange |
| CIK | — |
| Description | Aequus is a specialty pharmaceutical company, with a focus on commercializing value-added products in specialty therapeutic areas in the Canadian market. Aequus sales force currently markets third-party or exclusively licensed products for which the Company receives revenues from product sales or based upon a percentage of net sales. The Company continues to build its pipeline in ophthalmology and has recently added several commercial stage products through in-licensing agreements. Our commercial infrastructure is currently Canadian based, with specialty sales representatives currently available to promote specialty medicines to physicians and over the counter ("OTC") products to eye care professionals. Additional info from OTC: |
No news found.